Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Mar 19;125(12):1857-65.
doi: 10.1182/blood-2014-10-607341. Epub 2015 Jan 26.

An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults

Michael R Savona  1 , Luca Malcovati  2 , Rami Komrokji  3 , Ramon V Tiu  4 , Tariq I Mughal  5 , Attilio Orazi  6 , Jean-Jacques Kiladjian  7 , Eric Padron  3 , Eric Solary  8 , Raoul Tibes  9 , Raphael Itzykson  7 , Mario Cazzola  2 , Ruben Mesa  9 , Jaroslaw Maciejewski  4 , Pierre Fenaux  7 , Guillermo Garcia-Manero  10 , Aaron Gerds  4 , Guillermo Sanz  11 , Charlotte M Niemeyer  12 , Francisco Cervantes  13 , Ulrich Germing  14 , Nicholas C P Cross  15 , Alan F List  3 ; MDS/MPN International Working Group
Affiliations

An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults

Michael R Savona et al. Blood. .

Abstract

Myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPN) are hematologically diverse stem cell malignancies sharing phenotypic features of both myelodysplastic syndromes and myeloproliferative neoplasms. There are currently no standard treatment recommendations for most adult patients with MDS/MPN. To optimize efforts to improve the management and disease outcomes, it is essential to identify meaningful clinical and biologic end points and standardized response criteria for clinical trials. The dual dysplastic and proliferative features in these stem cell malignancies define their uniqueness and challenges. We propose response assessment guidelines to harmonize future clinical trials with the principal objective of establishing suitable treatment algorithms. An international panel comprising laboratory and clinical experts in MDS/MPN was established involving 3 independent academic MDS/MPN workshops (March 2013, December 2013, and June 2014). These recommendations are the result of this collaborative project sponsored by the MDS Foundation.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Classically, chronic myeloid malignancies are either proliferative or dysplastic. MDS/MPN that harbor hybrid characteristics of both MDS and MPN (overlap syndromes), represent a spectrum of different disorders.
See this image and copyright information in PMC

Comment in

References

    1. Orazi A, Germing U. The myelodysplastic/myeloproliferative neoplasms: myeloproliferative diseases with dysplastic features. Leukemia. 2008;22(7):1308–1319. - PubMed
    1. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937–951. - PubMed
    1. Foucar K. Myelodysplastic/myeloproliferative neoplasms. Am J Clin Pathol. 2009;132(2):281–289. - PubMed
    1. Elliott MA, Verstovsek S, Dingli D, et al. Monocytosis is an adverse prognostic factor for survival in younger patients with primary myelofibrosis. Leuk Res. 2007;31(11):1503–1509. - PubMed
    1. Mughal TCN, Padron E, Savona M, et al. Myelodysplastic/myeloproliferative neoplasms (MDS/MPN): an international perspective and recommendations on molecular pathogenesis and clinical characterization. Haematologica. In press. - PMC - PubMed

Publication types

MeSH terms